New & Publication by Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases.
IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance…
IBT Vaccines, a wholly owned subsidiary of Integrated Biotherapeutics Inc., announces it has received $3.9 million to advance the development of the IBT-V02 vaccine for Staphylococcus aureus induced recurrent skin and skin structure infections (SSSI). The funding is part of a $48 mil. investment in 8 companies by Novo Holding's REPAIR…
4 November 2019 INTEGRATED BIOTHERAPEUTICS TO PRESENT ON NOVEL VACCINES FOR MRSA AT WORLD ANTI-MICROBIAL CONGRESS 2019 Integrated Biotherapeutics, Inc. @ World Anti-Microbial Resistance Congress 2019 AN INDUSTRY EXPERTS CONFERENCE ON COMBATING ANTI-MICROBIAL RESISTANCE Maryland — 4 November 2019 – Integrated Biotherapeutics CEO Dr. M. Javad Aman will…
CARB-X global partnership headed toward developing an innovative vaccine against potentially deadly Staphylococcus aureus bacteria that could be a “game changer” in stemming antimicrobial resistance (AMR).
